Chengdu Olymvax Biopharmaceuticals (SHSE:688319) - Share price, News & Analysis

688319 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	3/6
Financial Health	4/6
Dividends	0/6

688319 Stock Overview

Olymvax Biopharmaceuticals Inc. develops and supplies vaccines.

Rewards

Earnings are forecast to grow 41.32% per year

Earnings grew by 47.7% over the past year

Risk Analysis

High level of non-cash earnings

Chengdu Olymvax Biopharmaceuticals Competitors

Getein Biotech

SHSE:603387

CN¥5.9b

Shenzhen Weiguang Biological Products

SZSE:002880

CN¥6.0b

Beijing Science Sun Pharmaceutical

SZSE:300485

CN¥5.3b

Hangzhou Biotest BiotechLtd

SHSE:688767

CN¥5.0b

Price History & Performance

Summary of all time highs, changes and price drops for Chengdu Olymvax Biopharmaceuticals
Historical stock prices
Current Share Price	CN¥13.91
52 Week High	CN¥40.59
52 Week Low	CN¥13.32
Beta	0
1 Month Change	-14.72%
3 Month Change	-23.99%
1 Year Change	-57.44%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-65.14%

Shareholder Returns

	688319	CN Biotechs	CN Market
7D	-1.0%	-1.0%	-3.3%
1Y	-57.4%	-33.6%	-19.2%

Return vs Industry: 688319 underperformed the CN Biotechs industry which returned -33.6% over the past year.

Return vs Market: 688319 underperformed the CN Market which returned -19.2% over the past year.

Price Volatility

Is 688319's price volatile compared to industry and market?
688319 volatility
688319 Average Weekly Movement	4.7%
Biotechs Industry Average Movement	5.0%
Market Average Movement	5.8%
10% most volatile stocks in CN Market	9.2%
10% least volatile stocks in CN Market	3.8%

Stable Share Price: 688319 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 688319's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2009	443	Shaowen Fan	https://www.olymvax.com

Olymvax Biopharmaceuticals Inc. develops and supplies vaccines. The company offers vaccines for Tetanus, a deadly infectious disease that causes nervous system toxicity by toxigenic clostridium tetanus; and haemophilus influenzae type b. it also develops vaccines for Staphylococcus aureus, a pathogenic bacterium that causes hospital infection and community infection; and Group A streptococcus disease. The company was founded in 2009 and is based in Chengdu, China.

Chengdu Olymvax Biopharmaceuticals Fundamentals Summary

How do Chengdu Olymvax Biopharmaceuticals's earnings and revenue compare to its market cap?
688319 fundamental statistics
Market Cap	CN¥5.64b
Earnings (TTM)	CN¥96.65m
Revenue (TTM)	CN¥550.74m

58.3x

P/E Ratio

10.2x

P/S Ratio

Is 688319 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
688319 income statement (TTM)
Revenue	CN¥550.74m
Cost of Revenue	CN¥37.92m
Gross Profit	CN¥512.82m
Other Expenses	CN¥416.17m
Earnings	CN¥96.65m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	0.24
Gross Margin	93.12%
Net Profit Margin	17.55%
Debt/Equity Ratio	11.4%

How did 688319 perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is 688319 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688319?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 688319. This is calculated by dividing 688319's market cap by their current preferred multiple.
What is 688319's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	CN¥5.64b

688319 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.7x
Enterprise Value/EBITDA	50.2x
PEG Ratio	1.4x

Price to Earnings Ratio vs Peers

How does 688319's PE Ratio compare to its peers?

688319 PE Ratio vs Peers

The above table shows the PE ratio for 688319 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PE	Estimated Growth	Market Cap
Peer Average	13.6x
603387 Getein Biotech	10.5x	n/a	CN¥5.9b
002880 Shenzhen Weiguang Biological Products	29.5x	n/a	CN¥6.0b
300485 Beijing Science Sun Pharmaceutical	9.5x	n/a	CN¥5.3b
688767 Hangzhou Biotest BiotechLtd	5x	n/a	CN¥5.0b
688319 Chengdu Olymvax Biopharmaceuticals	58.3x	41.3%	CN¥5.6b

Price-To-Earnings vs Peers: 688319 is expensive based on its Price-To-Earnings Ratio (58.3x) compared to the peer average (13.6x).

Price to Earnings Ratio vs Industry

How does 688319's PE Ratio compare vs other companies in the CN Biotechs Industry?

Price-To-Earnings vs Industry: 688319 is expensive based on its Price-To-Earnings Ratio (58.3x) compared to the CN Biotechs industry average (30x)

Price to Earnings Ratio vs Fair Ratio

What is 688319's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688319 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	58.3x
Fair PE Ratio	36.3x

Price-To-Earnings vs Fair Ratio: 688319 is expensive based on its Price-To-Earnings Ratio (58.3x) compared to the estimated Fair Price-To-Earnings Ratio (36.3x).

Share Price vs Fair Value

What is the Fair Price of 688319 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 688319's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 688319's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Chengdu Olymvax Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

41.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688319's forecast earnings growth (41.3% per year) is above the savings rate (3.2%).

Earnings vs Market: 688319's earnings (41.3% per year) are forecast to grow faster than the CN market (25.8% per year).

High Growth Earnings: 688319's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688319's revenue (29.3% per year) is forecast to grow faster than the CN market (18.1% per year).

High Growth Revenue: 688319's revenue (29.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688319's Return on Equity is forecast to be low in 3 years time (18.1%).

Discover growth companies

Past Performance

How has Chengdu Olymvax Biopharmaceuticals performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

52.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 688319 has a high level of non-cash earnings.

Growing Profit Margin: 688319's current net profit margins (17.5%) are higher than last year (17.3%).

Past Earnings Growth Analysis

Earnings Trend: 688319 has become profitable over the past 5 years, growing earnings by 52% per year.

Accelerating Growth: 688319's earnings growth over the past year (47.7%) is below its 5-year average (52% per year).

Earnings vs Industry: 688319 earnings growth over the past year (47.7%) exceeded the Biotechs industry 9.7%.

Return on Equity

High ROE: 688319's Return on Equity (11%) is considered low.

Discover strong past performing companies

Financial Health

How is Chengdu Olymvax Biopharmaceuticals's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: 688319's short term assets (CN¥892.8M) exceed its short term liabilities (CN¥386.7M).

Long Term Liabilities: 688319's short term assets (CN¥892.8M) exceed its long term liabilities (CN¥38.9M).

Debt to Equity History and Analysis

Debt Level: 688319 has more cash than its total debt.

Reducing Debt: 688319's debt to equity ratio has increased from 2.2% to 11.4% over the past 5 years.

Debt Coverage: 688319's debt is not well covered by operating cash flow (12.6%).

Interest Coverage: 688319 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

Dividend

What is Chengdu Olymvax Biopharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Chengdu Olymvax Biopharmaceuticals Dividend Yield vs Market

How does Chengdu Olymvax Biopharmaceuticals dividend yield compare to the market?
Segment	Dividend Yield
Company (Chengdu Olymvax Biopharmaceuticals)	n/a
Market Bottom 25% (CN)	0.5%
Market Top 25% (CN)	2.2%
Industry Average (Biotechs)	0.9%
Analyst forecast in 3 Years (Chengdu Olymvax Biopharmaceuticals)	n/a

Notable Dividend: Unable to evaluate 688319's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 688319's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 688319's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 688319's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 688319 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

12.8yrs

Average management tenure

CEO

Shaowen Fan (69 yo)

12.75yrs

Tenure

Mr. Shaowen Fan is Genenral Manager & Chairman of the Board of Chengdu Olymvax Biopharmaceuticals Inc. since 2019.

Leadership Team

Experienced Management: 688319's management team is seasoned and experienced (12.8 years average tenure).

Board Members

Experienced Board: 688319's board of directors are considered experienced (6.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 688319?
Owner Type	Number of Shares	Ownership Percentage
Institutions	25,267,704	6.2%
Private Companies	84,294,330	20.8%
Individual Insiders	120,064,403	29.6%
General Public	175,638,563	43.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 54.57% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
17.86%	Chongqing Wushan Biotechnology Co., Ltd.	72,394,330	CN¥1.0b	0%	no data
7.28%	Fan Fan	29,489,220	CN¥410.2m	0%	no data
6.39%	Pengfei Zhang	25,893,040	CN¥360.2m	0%	no data
5%	Yu Zhang	20,263,160	CN¥281.9m	-12.46%	no data
3.93%	Baolin Wang	15,922,077	CN¥221.5m	0%	no data
3.85%	Shaowen Fan	15,592,795	CN¥216.9m	0%	no data
2.94%	Shanghai Lianhuansheng Industry Co., Ltd.	11,900,000	CN¥165.5m	0%	no data
2.74%	GF Xinde Investment Management Co., Ltd	11,106,610	CN¥154.5m	0%	9.96%
1.64%	Cheng Hu	6,666,125	CN¥92.7m	0%	no data
1.2%	Hengjun Ma	4,858,946	CN¥67.6m	0%	no data
0.5%	Shanghai Panyao Asset Management Co., Ltd.	2,042,163	CN¥28.4m	0%	1.97%
0.25%	CITIC Securities Company Limited, Asset Management Arm	1,003,534	CN¥14.0m	0%	0.04%
0.17%	Shanghai Haitong Securities Asset Management Co., Ltd	672,789	CN¥9.4m	0%	0.17%
0.16%	Shanghai L&R Asset Management Company Limited	634,000	CN¥8.8m	0%	no data
0.13%	Great Wall Fund Management Co. Ltd.	544,582	CN¥7.6m	0%	0.03%
0.097%	China International Capital Corporation Hong Kong Asset Management Limited	392,854	CN¥5.5m	0%	0.04%
0.068%	Hongguang Li	277,440	CN¥3.9m	0%	no data
0.068%	Yong Tan	277,440	CN¥3.9m	0%	no data
0.051%	Lu Lu	208,080	CN¥2.9m	0%	no data
0.051%	Aimin Chen	208,080	CN¥2.9m	0%	no data
0.05%	Daoyuan Chen	204,000	CN¥2.8m	0%	no data
0.05%	Wei Wu	204,000	CN¥2.8m	0%	no data
0.038%	Golden Trust SinoPac Fund Management Co., Ltd.	152,000	CN¥2.1m	0%	0.02%
0.034%	CPIC Fund Management Co., Ltd.	136,436	CN¥1.9m	0%	0.01%
0.025%	Changsheng Fund Management Co., Ltd.	100,472	CN¥1.4m	0%	0.01%

Data	Last Updated (UTC time)
Company Analysis	2022/10/05 00:00
End of Day Share Price	2022/09/30 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31